|
Figure 1.1. New Active Substances
(NASs) Launched Worldwide, 1995–2004
Figure 1.2. The Drug Development
Process
Figure 1.3. Investment Escalation
per Successful Compound
Figure 1.4. Attrition during
the Clinical Development Process
Figure 2.1. Comparison of the Conventional and the Microdose
Approach to Candidate Selection
Figure 2.2. The Radiofrequency
Indentifier–Based Med-ic™ ECM™ Smart
Package for Clinical Supplies and Output from Med-ic™ Certi-Scan™ Software
Figure 2.3. Data Flow and Processing
in a Typical E-Clinical Trial
Figure 3.1. Projected Schematic
Development of Medicine and Healthcare toward Personalized Medicine
Figure 3.2. Representation of
Raw Data from a Clinical Trial that Allows Patients to be Clustered
Based on Drug Response
Figure 3.3. Schematic Representation
of the VOTES Clinical Trial Grid Computing Study
Figure 4.1. The FDA’s
Concept of the Three Dimensions of the “Critical Path” in
Drug Development
Table 2.1. F eatures of Typical
Electronic Patient-Reported Outcome Information Technology Tools
| 
